Therapeutic management of premenstrual syndrome

被引:24
作者
Freeman, Ellen W. [1 ,2 ]
机构
[1] Univ Penn, Dept Obstet Gynecol, Philadelphia, PA 19104 USA
[2] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA
关键词
menstrual disorders; oral contraceptives; PMS; premenstrual syndrome; serotonin reuptake inhibitors; treatment; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; DYSPHORIC DISORDER; LUTEAL-PHASE; ORAL-CONTRACEPTIVES; HYPERICUM-PERFORATUM; SERTRALINE TREATMENT; AGNUS CASTUS; EFFICACY; FLUOXETINE;
D O I
10.1517/14656566.2010.509344
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Importance of the field: Premenstrual syndrome (PMS) is among the most common health problems reported by reproductive-age women. Estimates indicate that up to 25% of women may warrant treatment for the distress or impaired functioning associated with the symptoms. Areas covered in this review: The primary focus of this review is the clinical condition of PMS and randomized, placebo-controlled trials of PMS treatment. A literature search in PubMed was conducted for these topics. The most recent reports of specific treatments in controlled treatment studies and all meta-analyses were selected. What the reader will gain: Reports consistently indicate that serotonergic antidepressants reduce PMS symptoms compared to a placebo. Hormonal treatments are the most widely prescribed medical treatment. Some oral contraceptives and gonadotropin-releasing hormone analogs have demonstrated efficacy, particularly for women who want contraception and PMS symptom control. Numerous non-pharmacologic treatments are utilized, but efficacy is reported only for calcium supplements, Vitex agnus castus (chasteberry), and cognitive-behavioral therapies. Further research to develop new therapies for the 40% of women with PMS who do not respond to the currently available treatments is needed. Take home message: There are treatments with demonstrated efficacy for PMS, and the majority of women can be helped.
引用
收藏
页码:2879 / 2889
页数:11
相关论文
共 106 条
[1]  
Altshuler L L, 2001, Postgrad Med, P1
[2]  
ANDERSCH B, 1978, BRIT J OBSTET GYNAEC, V85, P546
[4]   The epidemiology of perimenstrual psychological symptoms [J].
Angst, J ;
Sellaro, R ;
Stolar, M ;
Merikangas, KR ;
Endicott, J .
ACTA PSYCHIATRICA SCANDINAVICA, 2001, 104 (02) :110-116
[5]  
[Anonymous], 2000, OBSTET GYNECOL, V95, P1
[6]   ORAL-CONTRACEPTIVES IN PREMENSTRUAL-SYNDROME - A RANDOMIZED COMPARISON OF TRIPHASIC AND MONOPHASIC PREPARATIONS [J].
BACKSTROM, T ;
HANSSONMALMSTROM, Y ;
LINDHE, BA ;
CAVALLIBJORKMAN, B ;
NORDENSTROM, S .
CONTRACEPTION, 1992, 46 (03) :253-268
[7]   THE IMPACT OF ORAL-CONTRACEPTIVES ON THE EXPERIENCE OF PERIMENSTRUAL MOOD, CLUMSINESS, FOOD CRAVING AND OTHER SYMPTOMS [J].
BANCROFT, J ;
RENNIE, D .
JOURNAL OF PSYCHOSOMATIC RESEARCH, 1993, 37 (02) :195-202
[8]  
BERGER CP, 1994, OBSTET GYNECOL, V84, P379
[9]  
BERTONEJOHNSON ER, 2010, J STEROID BIOCH MOL
[10]  
BROWN CS, 1994, OBSTET GYNECOL, V84, P779